drugset / Trial / NCT00091338

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00091338 ↗

Treatment

Summary

RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Combining interleukin-7 with vaccine therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 when given with vaccine therapy in treating patients with metastatic melanoma.

Timeline

Start
2004-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-7 Protein / enzyme biologic — Subcutaneous
Background MART-1 antigen Vaccine — —
Background gp100 antigen Peptide — —
Background incomplete Freund's adjuvant Other / unclassified — Subcutaneous

Indications